Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation

Table 1 Subject baseline demographics and characteristics

Item		Subjects (n)	Rate (%)
Sex	Male	1038	58.1
	Female	749	41.9
Age (years)	0–14	86	4.8
	15–64	559	31.3
	65–74	491	27.5
	75–84	498	27.9
	≥ 85	149	8.3
	Unknown	4	0.2
Source of sepsis	Lungs	346	19.4
	Abdomen	396	22.2
	Urine	180	10.1
	Skin	48	2.7
	Focus-unknown	533	29.8
	Others	284	15.9
DIC score (JAAM criteria)	4	216	15.4
	5	368	26.3
	6	325	23.2
	7	191	13.6
	8	300	21.4
SOFA score	0–7	266	24.4
	8–10	270	24.8
	11–13	275	25.3
	≥ 14	278	25.5
SIRS score	2	394	24.4
	3	708	43.8
	4	513	31.8
Other anticoagulant treatment for DIC (Overall/after TM-α administration)		1,320/1,020	73.9/57.1
AT concentrate		876/476	49.0/26.6
Synthetic protease inhibitors		816/333	45.7/18.6
Heparin derivatives		427/212	23.9/11.9
Duration (days) of DIC before TM-α administration	0	1,134	63.5
	1	345	19.3
	2	110	6.2
	3	59	3.3
	4–6	78	4.4
	≥ 7	61	3.4

AT antithrombin, DIC disseminated intravascular coagulation, JAAM Japanese Association for Acute Medicine, SIRS systemic inflammatory response syndrome, SOFA Sequential Organ Failure Assessment, TM-α thrombomodulin alfa.

ISSN: 2052-0492